2-Bromo-1,3-Thiazole

The substitution pattern of 2-bromo-1,3-thiazole enables selective C–C bond formation at the 2-position under catalytic conditions that tolerate the electron-deficient thiazole ring. In a production-scale synthesis of the triazole antifungal agent voriconazole, this intermediate is cross-coupled with a 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine derivative via a Negishi-type procedure. The arylzinc reagent is generated at −78 °C in THF using zinc chloride and a Grignard precursor; subsequent addition of 2-bromo-1,3-thiazole at 1.15 molar equivalents relative to the pyrimidine electrophile, together with Pd(PPh₃)₄ at 0.5 mol%, achieves coupling within 90 minutes at 0–5 °C. Quenching into aqueous ammonium chloride and extraction with ethyl acetate are followed by solvent swap to heptane for crystallization. The isolated building block is then deprotected with concentrated hydrochloric acid in isopropanol at 40 °C to yield the hydrochloride salt that enters the final chiral resolution step. Process analytical technology (PAT) data collected on a 1000 L glass-lined reactor equipped with a Branson ultrasonication probe indicates that the rate-limiting zinc insertion is reproducible within a ±6% batch-to-batch yield tolerance when residual moisture is maintained below 50 ppm. Regulatory alignment follows the ICH Q7A guideline for active pharmaceutical ingredient GMP, with residual palladium controlled below 10 µg/g per USP ⟨232⟩ and the mutagenic impurity risk assessed under ICH M7 by an expert toxicologist. The immediate product of this stage is (2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, which is subsequently converted to voriconazole meeting EP 10.0, USP 43, and JP 18 specifications.

What Limits Palladium Turnover Number in Negishi Cross-Coupling with Thiazole Electrophiles?

In the kilogram-scale preparation of the BRAF inhibitor dabrafenib mesylate, 2-bromo-1,3-thiazole participates in a Suzuki–Miyaura reaction with a complex boronate ester under anhydrous conditions. The ester, derived from a proprietary 2-aminopyrimidine scaffold, is charged at 1.0 equivalent; 2-bromo-1,3-thiazole is used in 1.25 equivalents to compensate for protodebromination observed when the water content exceeds 600 ppm in the dioxane/water (4:1 v/v) mixture. The catalytic system employs Pd(dppf)Cl₂·CH₂Cl₂ at 2.0 mol% with powdered tripotassium phosphate (2.5 equivalents) at 85 °C jacket temperature. A recurring processing bottleneck arises from the formation of a highly insoluble Pd black precipitate when the agitation speed drops below 180 rpm in a 500 L reactor with a retreat-curve impeller, leading to catalyst deactivation and a yield drop from 88% to 47%. To mitigate this, the coupling step is executed under a nitrogen sparge (0.3 L/min) and monitored by in-situ Raman spectroscopy targeting the 1570 cm⁻¹ band of the C–Br stretch; the signal is integrated into a feedback loop that adjusts the jacket temperature to maintain a reaction rate of 0.05 mol% conversion per minute. Workup involves filtration through a Celite pad, liquid-liquid separation at 55 °C, and two successive recrystallizations from acetonitrile/water to achieve 99.3% purity by HPLC (area%). The dried product is transformed into the mesylate salt using methanesulfonic acid in acetone at −5 °C. This intermediate directly supplies the final C–N coupling with 1,2,4-triazole-3-carboxamide to produce dabrafenib mesylate (Tafinlar®). Control strategy documentation includes a critical process parameter matrix audited against FDA 21 CFR 211.110 and referencing the EP monograph for dabrafenib mesylate, with particular attention to the genotoxic impurity 2-aminopyrimidine (limit: 85 ppm).

2-Cyanothiazole as a Branch Point for Neonicotinoid Production

The conversion of 2-bromo-1,3-thiazole into 2-cyanothiazole is the pivotal step in a commercial route to the insecticide clothianidin, an agonist of the nicotinic acetylcholine receptor. In a high-boiling solvent mixture of sulfolane and dimethylacetamide (9:1 w/w), 2-bromo-1,3-thiazole (>99.5% GC purity) is combined with copper(I) cyanide (1.05 equivalents) at 140 °C under a dry nitrogen blanket. The heterogeneous reaction requires rigorous mechanical agitation in a 2000 L Alloy 20 reactor because the CuCN particles tend to settle; a triple-flight anchor stirrer at 78 rpm ensures suspension. The cyanide source particle size distribution is controlled to D50 = 8 µm by air-jet milling, as coarser grades have been shown to cause localized hotspots that generate the dimeric side product at levels exceeding 4.5%. After 18 hours, the conversion reaches >97%, and the crude is flash-distilled under 5 mbar vacuum (boiling point 78–82 °C) into a receiver containing butylated hydroxytoluene (500 ppm) to inhibit radical polymerization. 2-Cyanothiazole is then treated with chlorine gas in a photochemical flow reactor equipped with a 254 nm UV lamp to produce 2-chloro-5-chloromethylthiazole, which is nitrated with fuming nitric acid in sulfuric acid at −10 °C. The resulting nitramide is methylated with dimethyl sulfate in a biphasic water/toluene mixture, yielding clothianidin after a final hydrazinolysis and dehydrohalogenation step. The plant operates under a Process Safety Management framework with HAZOP revision recalling that residual bromine from incomplete substitution can react exothermically with dimethyl sulfate; therefore, the intermediate 2-cyanothiazole is sampled for bromide ion content via ion chromatography and must read below 20 µg/g before proceeding. FAO specification 582/TC (2020) and the US EPA tolerance at 40 CFR 180.586 define the acceptable residue profile of the final active ingredient.

Stille polycondensation between 2-bromo-1,3-thiazole and a 2,5-bis(trimethylstannyl)thiophene derivative produces an alternating donor–acceptor copolymer with a low bandgap suitable for organic photovoltaic donor application. The purified electron-deficient thiazole monomer is blended in a 1:0.98 molar ratio (slight excess of stannyl monomer) with benzo[1,2-b:4,5-b′]dithiophene distannane in anhydrous chlorobenzene (0.15 M total monomer concentration). The catalyst system comprises tris(dibenzylideneacetone)dipalladium(0) (2.5 mol%) and tri(o-tolyl)phosphine (10 mol%) and the mixture is heated under microwave irradiation (Biotage® Initiator+, 150 °C, 60 minutes, high absorption level) in sealed vials to achieve an Mn of 28 kDa with a dispersity of 2.1 as determined by SEC-MALLS in trichlorobenzene at 150 °C. Post-polymerization, the crude is precipitated into vigorously stirred methanol, collected by filtration, and subjected to sequential Soxhlet extraction with methanol (removes catalyst residues), acetone (oligomers), and hexane (low-MW fraction). The remaining hexane-insoluble fraction is finally extracted with chloroform, concentrated to 5% w/v, and spin-coated onto ITO-glass substrates in a glovebox (<0.1 ppm O₂, <0.1 ppm H₂O) to fabricate bulk heterojunction devices with PC₆₁BM as the acceptor. Power conversion efficiencies in inverted devices calibrated against NREL reference cell align with a certified value of 8.1% under standard AM 1.5G illumination. Residual tin content is measured by ICP-MS after microwave digestion and must comply with the 1000 µg/g limit established in the EU RoHS Directive 2011/65/EU, Annex II; palladium is controlled to ≤50 µg/g. This polymeric material appears in flexible OPV modules commercialized for IoT sensor powering.

2-Mercaptothiazole Production: A Nucleophilic Displacement Route

When a low-cost route to metalworking fluid biocides is required, 2-bromo-1,3-thiazole is transformed into 2-mercaptothiazole by treatment with sodium hydrogen sulfide in aqueous ethanol. In a 3000 L stainless-steel reactor, 2-bromo-1,3-thiazole (164 kg, 1.0 kmol) is heated to 95 °C with a 30% w/w aq. NaSH solution (187 kg, 2.0 kmol) in denatured ethanol (400 L). Off-gas from the exothermic displacement, primarily H₂S, is scrubbed with 10% sodium hydroxide in a packed column. After 4 hours the conversion surpasses 99%; the mixture is cooled to 5 °C and acidified with concentrated HCl to pH 3–4, precipitating crude 2-mercaptothiazole crystals that are filtered, washed with chilled deionized water, and dried under vacuum (50 °C, 10 mbar). The dried product is immediately formulated into a 50% active potassium salt solution with KOH for shipment as a tank preservative active under the EU Biocidal Products Regulation (BPR) 528/2012. The formulation is added to semi-synthetic cutting fluids at 0.15–0.3 wt% of the metalworking fluid concentrate to control bacterial growth; the active substance notification in Article 95 list is required.

The chelating ligand 2-(pyridin-2-yl)thiazole is synthesized on a 100 L scale by Suzuki cross-coupling of 2-bromo-1,3-thiazole with 2-pyridylboronic acid MIDA ester. The reaction is conducted in a 10:1 mixture of 1,4-dioxane and water at 70 °C using potassium carbonate (2.5 equivalents) and Pd-XPhos-G3 precatalyst (0.3 mol%). The electron-poor 2-bromo-1,3-thiazole is charged at 1.02 equivalents relative to the boronic ester to ensure complete consumption of the more costly pyridine reagent. Phase separation and vacuum distillation (bp 125 °C at 12 mmHg) yield the ligand with 99.7% GC purity. Subsequent coordination with copper(I) iodide in acetonitrile provides a luminescent Cu(I) complex used as an emitter dopant in organic light-emitting diodes. The batch record specifies a glovebox environment (<1 ppm moisture) for the metallation step to prevent formation of the non-emissive Cu(II) species that appears as a brown precipitate when the Karl Fischer reading exceeds 5 ppm.